THE IMPACT OF HYPERURICEMIA ON CARDIOVASCULAR RISK. REVIEW OF THE EXISTING LITERATURE
Abstract
Objectives: The aim of the current work was to assess, following analysis of existing and widely available literature, whether increased levels of uric acid in blood serum have an impact on increased cardiovascular risk, and is urate-lowering treatment beneficial.
Materials and Methods: A review was conducted using the PubMed database, limited to full-text, freely available publications from the past 10 years. The analysis focused primarily on randomized controlled trials, meta-analyses, and systematic reviews related to hyperuricemia and cardiovascular risk.
Results: The evidence indicates a consistent association between hyperuricemia and increased cardiovascular risk, including higher all-cause and cardiovascular mortality. Although threshold values for hyperuricemia varied across studies, cardiovascular risk was shown to rise even with levels above 5 mg/dl. SGLT2 inhibitors demonstrated both urate-lowering and cardioprotective effects. In contrast, traditional xanthine oxidase inhibitors (e.g., allopurinol, febuxostat) did not show a significant benefit in reducing cardiovascular events.
Conclusions: Hyperuricemia is an independent risk factor for the increase in mortality and other adverse cardiovascular outcomes. SGLT2 inhibitors have shown to be promising in improving cardiovascular prognosis, while xanthine oxidase inhibitors presented no advantages. Further research in this subject is suggested.
References
Braga, F., Pasqualetti, S., Ferraro, S., & Panteghini, M. (2016). Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: A systematic review and meta-analysis. Clinical Chemistry and Laboratory Medicine, 54(1), 7–15. https://doi.org/10.1515/CCLM-2015-0523,
Butt, J. H., Docherty, K. F., Claggett, B. L., Desai, A. S., Petersson, M., Langkilde, A. M., De Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Køber, L., Lam, C. S. P., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Shah, S. J., Vaduganathan, M., Jhund, P. S., Solomon, S. D., & McMurray, J. J. V. (2023). Association of Dapagliflozin Use with Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients with Heart Failure with and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. JAMA Cardiology, 8(4), 386–393. https://doi.org/10.1001/JAMACARDIO.2022.5608,
Cox, P., Gupta, S., Zhao, S. S., & Hughes, D. M. (2021). The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis. Rheumatology International, 41(7), 1209–1219. https://doi.org/10.1007/S00296-021-04876-6,
Deng, J. hao, Lai, P. hui, Xie, L. shan, Qiu, S. sheng, Qiu, D. sheng, & Zhang, J. xing. (2024). Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis. Clinical and Translational Science, 17(3). https://doi.org/10.1111/CTS.13757,
Doehner, W., Anker, S. D., Butler, J., Zannad, F., Filippatos, G., Coats, A. J. S., Ferreira, J. P., Henrichmoeller, I., Brueckmann, M., Schueler, E., Pocock, S. J., Januzzi, J. L., & Packer, M. (2024). Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial. JACC: Heart Failure, 12(12), 2057–2070. https://doi.org/10.1016/j.jchf.2024.08.020
Doehner, W., Anker, S. D., Butler, J., Zannad, F., Filippatos, G., Ferreira, J. P., Salsali, A., Kaempfer, C., Brueckmann, M., Pocock, S. J., Januzzi, J. L., & Packer, M. (2022). Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: The EMPEROR-reduced trial. European Heart Journal, 43(36), 3435–3446. https://doi.org/10.1093/EURHEARTJ/EHAC320,
Huang, G., Qin, J., Deng, X., Luo, G., Yu, D., Zhang, M., Zhou, S., & Wang, L. (2019). Prognostic value of serum uric acid in patients with acute heart failure A meta-analysis. Medicine (United States), 98(8). https://doi.org/10.1097/MD.0000000000014525,
Huang, W. M., Hsu, P. F., Cheng, H. M., Lu, D. Y., Cheng, Y. L., Guo, C. Y., Sung, S. H., Yu, W. C., & Chen, C. H. (2016). Determinants and prognostic impact of hyperuricemia in hospitalization for acute heart failure (xziiiiii, Trans.). Circulation Journal, 80(2), 404–410. https://doi.org/10.1253/CIRCJ.CJ-15-0964,
Kario, K., Nishizawa, M., Kiuchi, M., Kiyosue, A., Tomita, F., Ohtani, H., Abe, Y., Kuga, H., Miyazaki, S., Kasai, T., Hongou, M., Yasu, T., Kuramochi, J., Fukumoto, Y., Hoshide, S., & Hisatome, I. (2021). Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia. Journal of Clinical Hypertension, 23(2), 334–344. https://doi.org/10.1111/JCH.14153,
Kojima, S., Matsui, K., Hiramitsu, S., Hisatome, I., Waki, M., Uchiyama, K., Yokota, N., Tokutake, E., Wakasa, Y., Jinnouchi, H., Kakuda, H., Hayashi, T., Kawai, N., Mori, H., Sugawara, M., Ohya, Y., Kimura, K., Saito, Y., & Ogawa, H. (2019). Febuxostat for cerebral and cardiorenovascular events prevention study. European Heart Journal, 40(22), 1778-1786A. https://doi.org/10.1093/EURHEARTJ/EHZ119,
Kusunose, K., Yoshida, H., Tanaka, A., Teragawa, H., Akasaki, Y., Fukumoto, Y., Eguchi, K., Kamiya, H., Kario, K., Yamada, H., Sata, M., Node, K., Node, K., Murohara, T., Inoue, T., Sata, M., Ohishi, M., Yokote, K., Kario, K., … Kagiyama, M. (2022). Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study. Hypertension Research, 45(1), 106–115. https://doi.org/10.1038/S41440-021-00752-9,
Li, L., Chang, Y., Li, F., & Yin, Y. (2024). Relationship between serum uric acid levels and uric acid lowering therapy with the prognosis of patients with heart failure with preserved ejection fraction: a meta-analysis. Frontiers in Cardiovascular Medicine, 11. https://doi.org/10.3389/FCVM.2024.1403242/PDF
Li, M., Hu, X., Fan, Y., Li, K., Zhang, X., Hou, W., & Tang, Z. (2016). Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Scientific Reports, 6. https://doi.org/10.1038/SREP19520,
Liang, L., Hou, X., Bainey, K. R., Zhang, Y., Tymchak, W., Qi, Z., Li, W., & Banh, H. L. (2019). The association between hyperuricemia and coronary artery calcification development: A systematic review and meta-analysis. Clinical Cardiology, 42(11), 1079–1086. https://doi.org/10.1002/CLC.23266,
Lin, W. D., Deng, H., Guo, P., Liu, F. Z., Chen, R. Y., Fang, X. H., Zhan, X. Z., Liao, H. T., Huang, W. X., Liu, Y., Wang, F., Zheng, M. R., Liu, H. Z., Huang, J., Wei, W., Xue, Y. M., & Wu, S. L. (2019). High prevalence of hyperuricaemia and its impact on non-valvular atrial fibrillation: The cross-sectional Guangzhou (China) Heart Study. BMJ Open, 9(5). https://doi.org/10.1136/BMJOPEN-2018-028007,
Long, X., Wang, Z., & Yuan, W. (2025). Effects of febuxostat on heart failure patients with asymptomatic hyperuricaemia: A retrospective cohort study. BMJ Open , 15(7). https://doi.org/10.1136/BMJOPEN-2025-099442,
Mackenzie, I. S., Hawkey, C. J., Ford, I., Greenlaw, N., Pigazzani, F., Rogers, A., Struthers, A. D., Begg, A. G., Wei, L., Avery, A. J., Taggar, J. S., Walker, A., Duce, S. L., Barr, R. J., Dumbleton, J. S., Rooke, E. D., Townend, J. N., Ritchie, L. D., & Macdonald, T. M. (2024). Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation. Health Technology Assessment, 28(18). https://doi.org/10.3310/ATTM4092,
Maloberti, A., Colombo, V., Daus, F., De Censi, L., Abrignani, M. G., Temporelli, P. L., Binaghi, G., Colivicchi, F., Grimaldi, M., Gabrielli, D., Borghi, C., & Oliva, F. (2025). Two still unanswered questions about uric acid and cardiovascular prevention: Is a specific uric acid cut-off needed? Is hypouricemic treatment able to reduce cardiovascular risk? Nutrition, Metabolism and Cardiovascular Diseases, 35(3). https://doi.org/10.1016/j.numecd.2024.103792
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., Azizi, M., Benetos, A., Borghi, C., Hitij, J. B., Cifkova, R., Coca, A., Cornelissen, V., Cruickshank, J. K., Cunha, P. G., … Kjeldsen, S. E. (2023). 2023 ESH Guidelines for the management of arterial hypertension the Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension, 41(12), 1874–2071. https://doi.org/10.1097/HJH.0000000000003480,
Mengozzi, A., Pugliese, N. R., Desideri, G., Masi, S., Angeli, F., Barbagallo, C. M., Bombelli, M., Cappelli, F., Casiglia, E., Cianci, R., Ciccarelli, M., Cicero, A. F. G., Cirillo, M., Cirillo, P., Dell’Oro, R., D’Elia, L., Ferri, C., Galletti, F., Gesualdo, L., … Virdis, A. (2023). Serum Uric Acid Predicts All-Cause and Cardiovascular Mortality Independently of Hypertriglyceridemia in Cardiometabolic Patients without Established CV Disease: A Sub-Analysis of the URic acid Right for heArt Health (URRAH) Study. Metabolites, 13(2). https://doi.org/10.3390/METABO13020244,
Muszyński, P., Dąbrowski, E. J., Pasławska, M., Niwińska, M., Kurasz, A., Święczkowski, M., Tokarewicz, J., Kuźma, Ł., Kożuch, M., & Dobrzycki, S. (2023). Hyperuricemia as a Risk Factor in Hypertension among Patients with Very High Cardiovascular Risk. Healthcare (Switzerland), 11(17). https://doi.org/10.3390/HEALTHCARE11172460,
Nowak, M. M., Niemczyk, M., Gołębiewski, S., & Pączek, L. (2024). Influence of xanthine oxidase inhibitors on all-cause mortality in adults: A systematic review and meta-analysis. Cardiology Journal, 31(3), 479–487. https://doi.org/10.5603/CJ.97807,
Packer, M. (2024). Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure: JACC Review Topic of the Week. Journal of the American College of Cardiology, 83(2), 371–381. https://doi.org/10.1016/j.jacc.2023.10.030
Saito, Y., Tanaka, A., Ishizu, T., Yoshida, H., Kubota, Y., Nanasato, M., Matsuhisa, M., Ohya, Y., Kobayashi, Y., Node, K., Murohara, T., Inoue, T., Sata, M., Ohishi, M., Yokote, K., Kario, K., Watada, H., Shimomura, I., Matsuhisa, M., … Kagiyama, M. (2023). Factors associated with carotid intima-media thickness progression in patients with asymptomatic hyperuricemia: insights from the PRIZE study. Scientific Reports, 13(1). https://doi.org/10.1038/S41598-023-37183-0,
SN, V. P., Jaramillo, A. P., Yasir, M., Hussein, S., Singareddy, S., Iyer, N., & Nath, T. S. (2023). Hyperuricemia and Its Association With the Severity and Complications of Congestive Heart Failure: A Systematic Review. Cureus, 15(9). https://doi.org/10.7759/CUREUS.45246
Wang, Y., Zhang, X. Y., Gao, W. H., Du, M. F., Chu, C., Wang, D., Chen, C., Yuan, Y., Ma, Q., Liao, Y. Y., Yan, Y., Wang, K. K., Zhang, J., Gao, K., Li, C. H., Li, H., Hu, J. W., Zou, T., Sun, Y., … Chaudhry, K. (2020). Association of Uric Acid in Serum and Urine with Arterial Stiffness: Hanzhong Adolescent Hypertension Study. Disease Markers, 2020. https://doi.org/10.1155/2020/1638515,
White, W. B., Saag, K. G., Becker, M. A., Borer, J. S., Gorelick, P. B., Whelton, A., Hunt, B., Castillo, M., & Gunawardhana, L. (2018). Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. New England Journal of Medicine, 378(13), 1200–1210. https://doi.org/10.1056/NEJMOA1710895,
Xu, H., Liu, Y., Meng, L., Wang, L., & Liu, D. (2021). Effect of Uric Acid-Lowering Agents on Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Frontiers in Cardiovascular Medicine, 8. https://doi.org/10.3389/FCVM.2021.639392,
Yan, F., Zhang, Y., Pan, Y., Li, S., Yang, M., Wang, Y., Yanru, C., Su, W., Ma, Y., & Han, L. (2023). Prevalence and associated factors of mortality after percutaneous coronary intervention for adult patients with ST-elevation myocardial infarction: A systematic review and meta-analysis. Journal of Research in Medical Sciences, 28(1). https://doi.org/10.4103/JRMS.JRMS_781_21,
Zhang, E., Kou, L., Li, M., Ng, C. Y., Zhao, J., Li, G., & Liu, T. (2016). High uric acid level predicts left atrial thrombus or spontaneous echo contrast detected by transesophageal echocardiography: Meta-analysis and systematic review. Chronic Diseases and Translational Medicine, 2(1), 27–33. https://doi.org/10.1016/J.CDTM.2016.02.002
Zhong, C., Zhong, X., Xu, T., MD, T. X., & Zhang, Y. (2017). Sex-specific relationship between serum uric acid and risk of stroke: A dose-response meta-analysis of prospective studies. Journal of the American Heart Association, 6(4). https://doi.org/10.1161/JAHA.116.005042,
Zuo, T., Liu, X., Jiang, L., Mao, S., Yin, X., & Guo, L. (2016). Hyperuricemia and coronary heart disease mortality: A meta-analysis of prospective cohort studies. BMC Cardiovascular Disorders, 16(1). https://doi.org/10.1186/S12872-016-0379-Z,
Views:
0
Downloads:
0
Copyright (c) 2025 Mateusz Biszewski, Ida Dunder, Elżbieta Bebrysz, Jan Palmi, Karolina Dębek-Kalinowska, Piotr Bartnik, Jarosław Baran, Magdalena Koss, Aleksandra Drabik, Weronika Ziomek
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
